Document Detail

Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH.
MedLine Citation:
PMID:  12167397     Owner:  NLM     Status:  MEDLINE    
This article continues a series of reports on recent research developments in the field of heart failure. Reports of two key presentations made at the European Society of Cardiology Heart Failure Update meeting held in Oslo, Norway from 8 to 11 June 2002, are included in this article. Summaries of the results of the RENEWAL (RENAISSANCE and RECOVER) and ATTACH studies, presented at the Hot Line sessions held during the meeting are reported.
A P Coletta; A L Clark; P Banarjee; J G F Cleland
Related Documents :
16137107 - Challenges and opportunities in pan-european collaboration for researchers from central...
20374787 - European citizen and consumer attitudes and preferences regarding beef and pork.
7958117 - A review of the research requirements for europe to support legislation in the area of ...
12292527 - Chinese emigration to europe: combining european and chinese sources.
15680397 - Transgenic and gene knock-out techniques and burn research.
17462327 - Deceit and fraud in medical research.
Publication Detail:
Type:  Congresses    
Journal Detail:
Title:  European journal of heart failure     Volume:  4     ISSN:  1388-9842     ISO Abbreviation:  Eur. J. Heart Fail.     Publication Date:  2002 Aug 
Date Detail:
Created Date:  2002-08-08     Completed Date:  2002-10-29     Revised Date:  2011-06-08    
Medline Journal Info:
Nlm Unique ID:  100887595     Medline TA:  Eur J Heart Fail     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  559-61     Citation Subset:  IM    
Department of Academic Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, HU15 5JQ, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Heart Failure / drug therapy*
Immunoglobulin G / therapeutic use*
Randomized Controlled Trials as Topic*
Receptors, Tumor Necrosis Factor / therapeutic use*
Societies, Medical*
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 185243-69-0/TNFR-Fc fusion protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE s...
Next Document:  How patients with heart failure are managed in Portugal.